Future Market Insights7d
Global Nasal Allergy Treatment Market to Reach USD 13.3 Billion by 2033 at a CAGR of 6.7% | Data by Future Market Insights, Inc.
According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
pharmaphorum13d
GSK's Nucala gains US use in rare autoimmune disease
GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...
Yahoo Finance19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Pharmaceutical Technology19d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
GSK’s Nucala was approved in the US for severe asthma with an eosinophilic phenotype treatment. Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has ...
BioPharma Dive19d
Navigating future biopharma catalysts: What to expect at the 2025 J.P. Morgan Healthcare Conference
Bringing together over 8,000 industry leaders, emerging innovators and influential investors, the J.P. Morgan (JPM) Healthcare Conference is the most significant catalyst event for the healthcare ...
Daily20d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy ...
Pharmabiz21d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
Yahoo Finance21d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
ENDPOINTS NEWS22d
GSK’s Nu­cala bags an­oth­er Chi­na ap­proval, but biggest test yet to come
GSK’s block­buster res­pi­ra­to­ry drug Nu­cala has se­cured a Chi­na la­bel ex­pan­sion for cer­tain pa­tients with in­flamed si­nus­es. But a more im­por­tant chal­lenge on ...
ENDPOINTS NEWS22d
Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play
With the dis­ap­point­ment of No­vo Nordisk’s in­ject­ed Ca­griSe­ma in obe­si­ty at the end of 2024, ...
grafa22d
GSK's Nucala wins approval in China for CRSwNP treatment
GSK (NYSE:GSK) has announced the approval of its drug Nucala (mepolizumab) by the China National Medical Products Administration for treating adult patients with chronic rhinosinusitis with nasal ...